Comment
doi: 10.1016/j.ijrobp.2018.04.002.
Epub 2018 Aug 8.
Two Sides of the Same Coin: Head and Neck Cancer Treatment De-Intensification and Intensification with Induction Chemotherapy
- PMID: 31200811
- DOI: 10.1016/j.ijrobp.2018.04.002
Item in Clipboard
Comment
Two Sides of the Same Coin: Head and Neck Cancer Treatment De-Intensification and Intensification with Induction Chemotherapy
Int J Radiat Oncol Biol Phys.
.
No abstract available
Comment on
-
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.J Clin Oncol. 2017 Feb 10;35(5):490-497. doi: 10.1200/JCO.2016.68.3300. Epub 2016 Dec 28. J Clin Oncol. 2017. PMID: 28029303 Free PMC article. Clinical Trial.
-
Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.Lancet Oncol. 2017 Jun;18(6):803-811. doi: 10.1016/S1470-2045(17)30246-2. Epub 2017 Apr 20. Lancet Oncol. 2017. PMID: 28434660 Free PMC article. Clinical Trial.
-
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.Ann Oncol. 2017 Sep 1;28(9):2206-2212. doi: 10.1093/annonc/mdx299. Ann Oncol. 2017. PMID: 28911070 Clinical Trial.
Similar articles
-
nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma.Oral Oncol. 2017 Sep;72:26-31. doi: 10.1016/j.oraloncology.2017.07.001. Epub 2017 Jul 8. Oral Oncol. 2017. PMID: 28797458 Clinical Trial.
-
Treatment de-intensification strategies for head and neck cancer.Eur J Cancer. 2016 Nov;68:125-133. doi: 10.1016/j.ejca.2016.09.006. Epub 2016 Oct 15. Eur J Cancer. 2016. PMID: 27755996 Free PMC article. Review.
-
Cetuximab in Human Papillomavirus-Positive Oropharynx Carcinoma.J Clin Oncol. 2016 Apr 20;34(12):1289-91. doi: 10.1200/JCO.2015.65.1414. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884569 No abstract available.
-
A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):289-96. doi: 10.1016/j.ijrobp.2015.10.019. Epub 2015 Oct 22. Int J Radiat Oncol Biol Phys. 2016. PMID: 26675064 Clinical Trial.
-
Induction Chemotherapy With 5-Fluorouracil, Cisplatin, and Cetuximab in Advanced Head and Neck Squamous Cell Carcinoma.In Vivo. 2023 May-Jun;37(3):1275-1280. doi: 10.21873/invivo.13205. In Vivo. 2023. PMID: 37103108 Free PMC article. Review.
Cited by
-
Minichromosome maintenance protein 5 is an important pathogenic factor of oral squamous cell carcinoma.Oncol Lett. 2020 Oct;20(4):109. doi: 10.3892/ol.2020.11970. Epub 2020 Aug 10. Oncol Lett. 2020. PMID: 32831928 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
